Oncology/Hematology
News, opinions and meeting coverage in oncology/hematology.
鈥� "It really shows us that we have two great options," expert says
Latest in Oncology/Hematology
Gastric cancer incidence was lower after adjusting for certain factors in post hoc analyses
Also in TTHealthWatch: AACR report on cancer
Despite problematic dataset, risk/benefit profile not favorable with PD-L1 expression below 1
An increase in microbial risk score based on 22 bacteria tied to a 50% increase in HNSCC risk
Despite problematic dataset, risk/benefit profile not favorable with PD-L1 expression below 1
An increase in microbial risk score based on 22 bacteria tied to a 50% increase in HNSCC risk
Oncology/Hematology Case Studies
Rare condition can be deadly without early diagnosis and treatment
Nonspecific presentation impedes early diagnosis of rare indolent tumor in older man
Be aware of the potential for secondary malignancy in relation to LCH diagnosis, researchers urge
More in Oncology/Hematology
Study suggests differences in how the ACA cost-sharing exemption is applied across patient groups
Only a minority of patients adhered to SUNTRAC screening recommendations
News, features, and commentary about cancer-related issues
Air Force, Harvard Business School, clinical practice all part of Prasanth Reddy's resume
Benefits of voxelotor (Oxbryta) no longer outweigh the risks, Pfizer says
EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy
Actual rates for 2021 lagged behind projections
Fidanacogene elaparvovec reduces bleeding episodes by 71% after a single infusion
Strategy comes with associated "low risk" of delay in diagnosis of advanced or incurable cancers
Health news and commentary gathered by 成人B站猎奇版 staff
Other studies look at financial toxicity for teen/young adult cancer patients, nausea after chemo
Data since approvals suggest benefits limited to subgroups with PD-L1 expression of at least 1%
And a watchdog found they were retaliated against
Also in TTHealthWatch: youth and opioids, and pembrolizumab for triple-negative breast cancer
